RT Journal Article
T1 Systematic Therapeutic Drug Monitoring for Linezolid: Variability and Clinical Impact
A1 Alicia Galar, 
A1 Valerio Minero, Maricela
A1 Muñoz García, Patricia Carmen
A1 Alcalá, Luis
A1 García-González, Xandra
A1 Burillo Albizua, Almudena
A1 Sanjurjo, María
A1 Grau, Santiago
A1 Bouza Santiago, Emilio
AB Linezolid serum trough (Cmin) and peak (Cmax) levels were determined prospectively in 90 patients. Adequate exposure was defined as a Cmin of 2 to 8 mg/liter. Therapy was empirical (73.3%) or targeted (26.7%). Wide interindividual variability in linezolid Cmin levels was recorded (0.1 to 25.2 μg/ml). Overall, 65.5% of the patients had out-of-range, 41.1% had subtherapeutic, and 24.4% had supratherapeutic trough levels. We did not find a correlation between abnormal levels and adverse events, in-hospital mortality, or overall poor outcome.
PB American Society for Microbiology
SN 0066-4804
SN 1098-6596
YR 2017
FD 2017
LK https://hdl.handle.net/20.500.14352/116861
UL https://hdl.handle.net/20.500.14352/116861
LA eng
NO Galar A, Valerio M, Muñoz P, Alcalá L, García-González X, Burillo A, Sanjurjo M, Grau S, Bouza E. Systematic Therapeutic Drug Monitoring for Linezolid: Variability and Clinical Impact. Antimicrob Agents Chemother. 2017 Sep 22;61(10):e00687-17. doi: 10.1128/AAC.00687-17. PMID: 28739788; PMCID: PMC5610525.
DS Docta Complutense
RD 20 dic 2025